|
WO2007031734A1
(en)
|
2005-09-14 |
2007-03-22 |
Ucb Pharma S.A. |
Comb polymers
|
|
CA2632628C
(en)
|
2005-12-09 |
2016-01-19 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human il-6
|
|
MX2009002855A
(es)
*
|
2006-09-15 |
2009-03-30 |
Enzon Pharmaceuticals Inc |
Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
US9319225B2
(en)
|
2007-01-16 |
2016-04-19 |
Microsoft Technology Licensing, Llc |
Remote device waking using a multicast packet
|
|
EP2535350B1
(de)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Antikörperfusionen mit Doppelspezifität
|
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
|
US8034396B2
(en)
*
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
|
WO2010095052A2
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Compounds and medical devices activated with solvophobic linkers
|
|
US9273191B2
(en)
|
2009-02-21 |
2016-03-01 |
Sofradim Production |
Medical devices with an activated coating
|
|
US9039979B2
(en)
|
2009-02-21 |
2015-05-26 |
Sofradim Production |
Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
|
|
US8663689B2
(en)
*
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
US8956603B2
(en)
|
2009-02-21 |
2015-02-17 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
EP2398524B1
(de)
|
2009-02-21 |
2017-07-12 |
Covidien LP |
Medizinische vorrichtungen mit aktivierten oberflächen
|
|
CA2753179A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same by extrusion
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
US8877170B2
(en)
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
EP2398584A2
(de)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Vorrichtung und verfahren zum erreichen von polymeren durch exposition mit uv-strahlung zur herstellung von injizierbaren medizinischen vorrichtungen
|
|
EP2398523B1
(de)
|
2009-02-21 |
2018-04-04 |
Covidien LP |
Medizinische vorrichtungen mit aktivierten oberflächen
|
|
CA2753171A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same using uv radiation
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
US8968733B2
(en)
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
GB0903207D0
(en)
|
2009-02-25 |
2009-04-08 |
Ucb Pharma Sa |
Method for expressing multimeric proteins
|
|
WO2010097435A1
(en)
|
2009-02-25 |
2010-09-02 |
Ucb Pharma, S.A. |
Method for producing antibodies
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
WO2011023680A2
(en)
|
2009-08-24 |
2011-03-03 |
Cytos Biotechnology Ag |
Processes for the synthesis and purification of heterobifunctional cross-linkers
|
|
GB0916881D0
(en)
*
|
2009-09-25 |
2009-11-11 |
Electrophoretics Ltd |
Mass labels
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
CN102781963B
(zh)
|
2009-10-27 |
2018-02-16 |
Ucb医药有限公司 |
功能修饰性NAv1.7抗体
|
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2794336A1
(en)
|
2010-03-25 |
2011-09-29 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
US8795331B2
(en)
|
2010-03-25 |
2014-08-05 |
Covidien Lp |
Medical devices incorporating functional adhesives
|
|
EP2588525A4
(de)
|
2010-06-29 |
2015-06-10 |
Covidien Lp |
Mikrowellengesteuerter reaktor und verfahren zur in-situ-formung von implantaten
|
|
US8865857B2
(en)
|
2010-07-01 |
2014-10-21 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
WO2012014080A2
(en)
|
2010-07-27 |
2012-02-02 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
PH12013501435B1
(en)
|
2011-01-14 |
2019-02-01 |
UCB Biopharma SRL |
Antibody molecules which bind il-17a and il-17f
|
|
WO2012125775A1
(en)
|
2011-03-16 |
2012-09-20 |
Sanofi |
Uses of a dual v region antibody-like protein
|
|
CN103459366B
(zh)
*
|
2011-03-30 |
2015-04-15 |
富士胶片株式会社 |
聚醚化合物、使用了该聚醚化合物的固化剂以及该聚醚化合物的制造方法
|
|
BR112014006175B1
(pt)
|
2011-09-16 |
2020-02-11 |
Ucb Pharma S.A. |
Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
|
|
JP6411214B2
(ja)
|
2011-11-11 |
2018-10-24 |
ユーシービー バイオファルマ エスピーアールエル |
アルブミン結合抗体及びその結合断片
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
US10048253B2
(en)
|
2012-06-28 |
2018-08-14 |
Ucb Biopharma Sprl |
Method for identifying compounds of therapeutic interest
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
KR102272932B1
(ko)
|
2013-10-25 |
2021-07-05 |
싸이오서스 테라퓨틱스 엘티디. |
이종 유전자로 무장된 종양살상 아데노바이러스
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
KR20170138570A
(ko)
|
2015-04-30 |
2017-12-15 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP6851322B2
(ja)
|
2015-05-27 |
2021-03-31 |
ユーシービー バイオファルマ エスアールエル |
神経疾患を治療する方法
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
SG10202010735PA
(en)
|
2015-07-06 |
2020-11-27 |
UCB Biopharma SRL |
Tau-binding antibodies
|
|
CA2991264C
(en)
|
2015-07-06 |
2023-10-10 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
EP3359688B1
(de)
|
2015-10-05 |
2021-06-16 |
UCB Biopharma SRL |
Molekulare signaturen zur verwendung bei der diagnose und analyse des ansprechens auf eine behandlung bei autoimmunkrankheiten
|
|
CN108350068A
(zh)
|
2015-10-27 |
2018-07-31 |
Ucb生物制药私人有限公司 |
使用抗-il-17a/f抗体的治疗方法
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7328761B2
(ja)
|
2016-01-11 |
2023-08-17 |
インヒブルクス インコーポレイテッド |
多価多重特異性ox40結合融合タンパク質
|
|
CN109071643B
(zh)
|
2016-05-01 |
2024-03-19 |
Ucb生物制药有限责任公司 |
亲和力改造的血清蛋白载体结合结构域
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
EP3504244A4
(de)
|
2016-08-26 |
2020-08-19 |
Agency for Science, Technology and Research |
Makrophagenstimulierender proteinrezeptor (oder ron - recepteur d' origine nantais)-antikörper und verwendungen davon
|
|
KR102491752B1
(ko)
|
2016-08-29 |
2023-01-26 |
싸이오서스 테라퓨틱스 엘티디. |
이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
|
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
EP3824906A1
(de)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antikörperformulierungen
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
US12168054B2
(en)
|
2017-05-19 |
2024-12-17 |
Syndax Pharmaceuticals, Inc. |
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
|
|
AU2018277294B2
(en)
|
2017-06-01 |
2025-04-24 |
Akamis Bio Limited |
Oncolytic virus and method
|
|
JP2020533976A
(ja)
|
2017-09-05 |
2020-11-26 |
グラディエーター バイオサイエンシーズ インコーポレイテッド |
エキソソームを標的化する方法
|
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
|
AU2019289176B2
(en)
|
2018-06-18 |
2026-02-19 |
Adelaide university |
Gremlin-1 antagonist for the prevention and treatment of cancer
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
AU2019321490B2
(en)
|
2018-08-13 |
2025-09-04 |
Inhibrx Biosciences, Inc. |
Ox40-binding polypeptides and uses thereof
|
|
JP7518821B2
(ja)
|
2018-10-16 |
2024-07-18 |
ユーシービー バイオファルマ エスアールエル |
重症筋無力症の治療方法
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2020197502A1
(en)
|
2019-03-26 |
2020-10-01 |
Aslan Pharmaceuticals Pte Ltd |
Treatment employing anti-il-13r antibody or binding fragment thereof
|
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
EP4108683A4
(de)
|
2020-02-21 |
2024-04-03 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-il-2-antikörper, antigenbindendes fragment davon und medizinische verwendung davon
|
|
TW202144429A
(zh)
|
2020-05-14 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗cd25抗體、其抗原結合片段及其醫藥用途
|
|
BR112022026533A2
(pt)
|
2020-07-02 |
2023-01-17 |
Beijing Tuo Jie Biopharmaceutical Co Ltd |
Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
|
|
EP4190812A4
(de)
|
2020-07-27 |
2024-09-04 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Anti-cd79b-antikörper-wirkstoff-konjugat sowie herstellungsverfahren dafür und pharmazeutische verwendung davon
|
|
WO2022079036A1
(en)
|
2020-10-13 |
2022-04-21 |
Almirall, S.A. |
Bispecific molecules and methods of treatment using the same
|
|
CA3198049A1
(en)
|
2020-10-15 |
2022-04-21 |
UCB Biopharma SRL |
Binding molecules that multimerise cd45
|
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
|
WO2022228364A1
(zh)
|
2021-04-25 |
2022-11-03 |
江苏恒瑞医药股份有限公司 |
抗masp2抗体、其抗原结合片段及医药用途
|
|
EP4365200A4
(de)
|
2021-06-28 |
2025-04-09 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-cd40-antikörper, antigenbindendes fragment und medizinische verwendung davon
|
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
|
MX2024001877A
(es)
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
CA3229503A1
(en)
|
2021-08-25 |
2023-03-02 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing fusion protein
|
|
JP2024535793A
(ja)
|
2021-09-15 |
2024-10-02 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Pd-1に特異的に結合するタンパク質及びその医薬的使用
|
|
WO2023075702A1
(en)
|
2021-10-29 |
2023-05-04 |
Aslan Pharmaceuticals Pte Ltd |
Anti-il-13r antibody formulation
|
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
|
EP4477673A4
(de)
|
2022-02-11 |
2025-09-03 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Immunokonjugat und dessen verwendung
|
|
TW202337905A
(zh)
|
2022-02-23 |
2023-10-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體之糖基化形式
|
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
|
KR20250075749A
(ko)
|
2022-08-26 |
2025-05-28 |
아슬란 파마슈티컬스 피티이 엘티디 |
항-il13r 항체의 고농도 제형
|
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|
|
EP4626549A1
(de)
|
2022-11-28 |
2025-10-08 |
UCB Biopharma SRL |
Behandlung von fibromyalgie
|
|
CN120282801A
(zh)
|
2022-12-28 |
2025-07-08 |
苏州盛迪亚生物医药有限公司 |
一种cd40结合分子的组合物及医药用途
|
|
EP4681729A4
(de)
|
2023-03-15 |
2026-07-15 |
Shanghai Mabgen Biotech Ltd |
Pharmazeutische zusammensetzung mit pd-1/pvrig/tigit-bindungsprotein und medizinische verwendung davon
|
|
TW202508641A
(zh)
|
2023-08-16 |
2025-03-01 |
大陸商上海邁晉生物醫藥科技有限公司 |
一種包含免疫綴合物的醫藥組成物及其用途
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
TW202540204A
(zh)
|
2024-01-26 |
2025-10-16 |
西班牙商阿爾米雷爾有限公司 |
雙特異性分子及使用其的治療方法
|
|
GB202403366D0
(en)
|
2024-03-08 |
2024-04-24 |
Univ Oxford Innovation Ltd |
Product
|
|
WO2025196217A1
(en)
|
2024-03-21 |
2025-09-25 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|
|
WO2026027660A1
(en)
|
2024-08-02 |
2026-02-05 |
UCB Biopharma SRL |
Formulations of anti-gremlin-1 antibodies
|
|
WO2026057816A1
(en)
|
2024-09-13 |
2026-03-19 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|